The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2–17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in chil...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambrose, C. S., Dubovsky, F., Yi, T., Belshe, R. B., Ashkenazi, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456911/
https://www.ncbi.nlm.nih.gov/pubmed/22410646
http://dx.doi.org/10.1007/s10096-012-1595-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456911/
https://www.ncbi.nlm.nih.gov/pubmed/22410646
http://dx.doi.org/10.1007/s10096-012-1595-9

Ejemplares similares